Art. -Nr.: HY-10234

Saracatinib

(Synonyms: AZD0530)

43 Cited Publications

Kundenbewertung

Based on 43 publication(s) in Google Scholar

Saracatinib (AZD0530) is a potent Src family inhibitor with IC₅₀s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.23%
CAS. Nr.: 379231-04-6
Formel: C₂₇H₃₂ClN₅O₅
Molecular Weight:542.03

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Saracatinib Chemical Structure

CAS. Nr.: 379231-04-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (43)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 2.7 nM (Src), 30 nM (v-Abl), 66 nM (EGFR), 200 nM (c-Kit)^[1]

Alle Src Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.14 μM Compound: 33, AZD-0530	Inhibition of A549 cell migration by microdroplet migration assay Inhibition of A549 cell migration by microdroplet migration assay	[PMID: 17064066]
HeLa	IC₅₀	2.4 μM Compound: 30	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth inhibition Antiproliferative activity against human HeLa cells assessed as reduction in cell growth inhibition	[PMID: 32539378]
Huh-7	CC₅₀	>50 μM Compound: 46	Cytotoxicity against human Huh-7 cells Cytotoxicity against human Huh-7 cells	[PMID: 32283298]
Huh-7	CC₅₀	>50 μM Compound: Saracatinib	Cytotoxicity against human Huh-7 cells Cytotoxicity against human Huh-7 cells	[PMID: 34081439]
Huh-7	CC₅₀	74 μM Compound: 43; AZD0530	Cytotoxicity against human Huh-7 cells Cytotoxicity against human Huh-7 cells	[PMID: 33539089]
HUVEC	IC₅₀	>5 μM Compound: 33, AZD-0530	Inhibition of FGF-stimulated HUVEC cell growth Inhibition of FGF-stimulated HUVEC cell growth	[PMID: 17064066]
HUVEC	IC₅₀	>5 μM Compound: 33, AZD-0530	Inhibition of VEGF-stimulated HUVEC cell growth Inhibition of VEGF-stimulated HUVEC cell growth	[PMID: 17064066]
K562	IC₅₀	220 nM Compound: 33, AZD-0530	Antiproliferative activity against huamn K562 cell line Antiproliferative activity against huamn K562 cell line	[PMID: 17064066]
NIH3T3	IC₅₀	0.0027 μM Compound: 33, AZD-0530	Inhibition of human c-Src in NIH3T3 cells Inhibition of human c-Src in NIH3T3 cells	[PMID: 17064066]
NIH3T3	IC₅₀	0.076 μM Compound: 33, AZD-0530	Antiproliferative activity against mouse NIH3T3 cell line transfected with c-SRC Antiproliferative activity against mouse NIH3T3 cell line transfected with c-SRC	[PMID: 17064066]
SJRH30	IC₅₀	10.1 μM Compound: 2, NCGC00241099	Antiproliferative activity against human Rh30 cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human Rh30 cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 23787099]
Vero	CC₅₀	>50 μM Compound: 30	Cytotoxicity against African green monkey Vero cells by MTT assay Cytotoxicity against African green monkey Vero cells by MTT assay	[PMID: 32539378]
Vero C1008	EC₅₀	10 μM Compound: Saracatinib	Antiviral activity against MERS-CoV infected in african green monkey Vero E6 Antiviral activity against MERS-CoV infected in african green monkey Vero E6	[PMID: 37597435]

In Vitro

Saracatinib (AZD0530), an orally available Src inhibitor, demonstrates potent antimigratory and anti-invasive effects in vitro, and inhibits metastasis in a murine model of bladder cancer. Antiproliferative activity of Saracatinib varies between cell lines (IC₅₀ of 0.2-10 μM). Saracatinib potently inhibits the proliferation of Src3T3 mouse fibroblasts and demonstrates variable antiproliferative activity in a range of human cancer cell lines containing endogenous Src. Sub micromolar growth inhibition of five of the human cancer cell lines tested with Saracatinib (tumor types: colon, prostate, lung, and leukemia) is observed with IC₅₀ values of 0.2-0.7 μM. In 3-day MTS cell proliferation assays, Saracatinib inhibits proliferation of the Bcr-Abl-driven human leukemia cell line K562 with an IC₅₀ of 0.22 μM. In the microdroplet migration assay, Saracatinib reduces the migration of human lung cancer A549 cells in a concentration-dependent manner (IC₅₀ 0.14 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Saracatinib (AZD0530) treatment potently inhibits the proliferation of subcutaneously transplanted Src3T3 fibroblasts in mice and rats in a dose-dependent manner. In both models, significant inhibition of tumor growth is seen at doses ≥6 mg/kg/day (60% inhibition in mice and 98% inhibition in rats versus animals treated with vehicle) and, at the maximum doses investigated, complete tumor growth inhibition is observed (100% inhibition at 25 mg/kg/day in mice and 10 mg/kg/day in rats)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 379231-04-6
Appearance Solid
Molecular Weight 542.03
Formel C₂₇H₃₂ClN₅O₅
Color White to light yellow
SMILES

ClC1=CC=C2C(OCO2)=C1NC3=C4C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=CC4=NC=N3
Synonyms

AZD0530
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (43)

All WB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with β-catenin. [Abstract]

2023 Feb 17;8(1):66. PMID: 36797256

Saracatinib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Feb 17;8(1):66. [Abstract]

Saracatinib (10 μM) reduces BLK-mediated FAM83A tyrosine phosphorylation in HEK293T cells.
Cancer Res

Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. [Abstract]

2024 Feb 1;84(3):479-492. PMID: 38095536
Nat Commun

p38 mediated ACSL4 phosphorylation drives stress-induced esophageal squamous cell carcinoma growth through Src myristoylation. [Abstract]

2025 Apr 7;16(1):3319. PMID: 40195298
Nat Commun

TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. [Abstract]

2023 Apr 24;14(1):2342. PMID: 37095176
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Neuro Oncol

MBD3 deficiency decommissions the NuRD complex and orchestrates the epigenetic regulation of gene expression to suppress neuroblastoma progression. [Abstract]

2026 Jan 7:noaf297. PMID: 41499431
Cell Death Dis

Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway. [Abstract]

2025 Feb 3;16(1):64. PMID: 39900894
Cell Death Dis

Hippo signaling suppresses tumor cell metastasis via a Yki-Src42A positive feedback loop. [Abstract]

2021 Dec 3;12(12):1126. PMID: 34862372
Cell Death Dis

FYN is required for ARHGEF16 to promote proliferation and migration in colon cancer cells. [Abstract]

2020 Aug 7;11(8):652. PMID: 32811808
Int J Biol Sci

Macrophage KDM2A promotes atherosclerosis via regulating FYN and inducing inflammatory response. [Abstract]

2025 Mar 31;21(6):2780-2805. PMID: 40303308
Phytomedicine

Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer. [Abstract]

2025 Oct 8:148:157387. PMID: 41106095
EBioMedicine

Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model. [Abstract]

2022 Dec:86:104374. PMID: 36455410
Acta Neuropathol

Fyn-dependent Tau microcluster formation seeds and boosts extensive Tau pathology. [Abstract]

2025 May 14;149(1):48. PMID: 40366450
J Orthop Translat

Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway. [Abstract]

2022 Feb 16:33:55-69. PMID: 35228997
Leukemia

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. [Abstract]

2012 Oct;26(10):2233-44. PMID: 22469781
Int J Biol Macromol

SLC39A1 promotes pancreatic cancer metastasis by elevating intracellular zinc and activating the Src/FAK signaling pathway. [Abstract]

2026 May 27:152746. PMID: 42208832
Int J Biol Macromol

Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma. [Abstract]

2026 Jan:336:149150. PMID: 41274476
Cell Mol Gastroenterol Hepatol

Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability. [Abstract]

2021;11(3):683-696. PMID: 33075564
Cell Rep

Nociceptor-derived Reg3γ prevents endotoxic death by targeting kynurenine pathway in microglia. [Abstract]

2022 Mar 8;38(10):110462. PMID: 35263589
Cell Prolif

PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness. [Abstract]

2023 Jan;56(1):e13337. PMID: 36127291
Cancer Cell Int

Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation. [Abstract]

2021 Dec 7;21(1):655. PMID: 34876150
Mol Cancer Ther

Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. [Abstract]

2017 Nov;16(11):2387-2398. PMID: 28775147
Biochem Pharmacol

Divergent mechanisms, unified therapy: saracatinib targets Src/HIF signaling in endothelial and microglial cells to treat retinopathy. [Abstract]

2026 Aug;250(Pt 2):118028. PMID: 42070593
Biochem Pharmacol

WISP-3 drives LUAD metastasis by suppressing miR-5004-5p to upregulate MMP-12. [Abstract]

2026 Jun 25;251(Pt 2):118189. PMID: 42349620
Biochem Pharmacol

IFITM1 promotes proliferation, migration and macrophage-like transdifferentiation of vascular smooth muscle cells via c-Src/MAPK/GATA2/E2F2 pathway in atherosclerosis. [Abstract]

2025 Jun 2:239:117014. PMID: 40466954
Int J Mol Sci

(20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2. [Abstract]

2021 Aug 27;22(17):9289. PMID: 34502195
Cancer Sci

PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells. [Abstract]

2018 Jun;109(6):1949-1957. PMID: 29601121
Cell Signal

Annexin A2 binds the 3'-UTR of H2AX mRNA and regulates histone-H2AX-derived hypoxia-inducible factor 1-alpha activation. [Abstract]

2025 Mar 29:111781. PMID: 40164417
J Cell Mol Med

Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion. [Abstract]

2019 Apr;23(4):2399-2409. PMID: 30677226

Saracatinib purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]

Immunoblot analysis of p-JNK1/2 (T183/Y185) in HepG2 cells treated with saracatinib (10 μM, 12 h) and PP1 (10 μM, 2 h).
Oncol Rep

Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. [Abstract]

2018 Aug;40(2):635-646. PMID: 29917168
iScience

Inhibition of SRC-mediated integrin signaling in bone marrow niche enhances hematopoietic stem cell function. [Abstract]

2022 Sep 19;25(10):105171. PMID: 36204266
J Virol

Role of Src family kinases Fyn and Lyn in arenavirus infection. [Abstract]

2026 Apr 21;100(4):e0024126. PMID: 41914886
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Arch Biochem Biophys

miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. [Abstract]

2018 May 1:645:54-60. PMID: 29550144

Saracatinib purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2018 May 1:645:54-60. [Abstract]

SK-BR-3, MCF-7, and MDA-MB-231 cells are treated with 1 μM Saracatinib for 48 h. After treatment, the Src protein expression is determined by western blot.
Res Sq

2026 May 20.
Preprints

2025 Sep 22.
bioRxiv

PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]

2024 Nov 6:2024.11.04.621884. PMID: 39574568
bioRxiv

2024 July 09.
bioRxiv

2023 Dec 14.
Biomed Pharmacother

Periplocin ameliorates mouse age-related meibomian gland dysfunction through up-regulation of Na/K-ATPase via SRC pathway. [Abstract]

2021 Dec 6;146:112487. PMID: 34883449
Research Square Preprint

2021 Jul.
Technical University of Munich

24.01.2018.
Oncotarget

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. [Abstract]

2015 Sep 29;6(29):27160-75. PMID: 26320174

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (92.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8449 mL

9.2246 mL

18.4492 mL

5 mM

0.3690 mL

1.8449 mL

3.6898 mL

10 mM

0.1845 mL

0.9225 mL

1.8449 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

Investigation of the reversibility and the mechanism of Saracatinib inhibition is conducted using a full-length activated human Src in a continuous, coupled assay. ATP and peptide substrate (Src II peptide) concentrations are varied in turn (ATP 40-1280 μM; Src II peptide 100-800 μM), in conjunction with Saracatinib (0-30 nM), at saturating concentrations of the non-varied substrate (ATP 1.6 mM; Src II peptide 1.0 mM). The binding affinity of Saracatinib for inactivated Src (phosphorylated at tyrosine 527, not tyrosine 416) is measured using a BIAcore inhibition-in-solution assay. The assay followed competition binding between Saracatinib and an immobilized ureidoquinazoline for binding to Src. Data analysis is performed by unweighted nonlinear regression using GraFit, version 5 and an F-test is used to identify the most suitable equation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Cell proliferation is assessed using a colorimetric 5-bromo-2′-deoxyuridine (BrdU) Cell Proliferation ELISA kit. Briefly, cells are plated onto 96-well plates (1.5×10⁴ cells/well), the following day 0.039-20 μM Saracatinib in DMSO (at a final concentration of 0.5%) is added and the cells are incubated for 24 h. The cells are pulse labeled with BrdU for 2 h and fixed. Cellular DNA is then denatured with the provided solution and incubated with antiBrdU peroxidase for 90 min. Following three washes with phosphate-buffered saline, tetramethylbenzidine substrate solution is added and the plates are incubated on a plate shaker for 10-30 min until the positive control absorbance at 690 nm is approximately 1.5 absorbance units^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice and Rats^[1]
Female athymic mice (nu/nu) and rats (RH-rnu/rnu) are used. Animals are treated once daily by oral gavage with either vehicle alone or Saracatinib 6.25-50 mg/kg for 10-91 days. Tumor growth inhibition is calculated. For pharmacokinetic and pharmacodynamic analysis animals are humanely sacrificed and samples (plasma and tumor) are collected. Tumor samples are homogenized with 5 volumes of water and extracted with chloroform. Plasma and tumor samples are analyzed for Saracatinib concentration using high-performance liquid chromatography with tandem mass spectrometric detection after solid-phase extraction.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3(3), 248-261. [Content Brief]

[2]. Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8449 mL	9.2246 mL	18.4492 mL	46.1229 mL
	5 mM	0.3690 mL	1.8449 mL	3.6898 mL	9.2246 mL
	10 mM	0.1845 mL	0.9225 mL	1.8449 mL	4.6123 mL
	15 mM	0.1230 mL	0.6150 mL	1.2299 mL	3.0749 mL
	20 mM	0.0922 mL	0.4612 mL	0.9225 mL	2.3061 mL
	25 mM	0.0738 mL	0.3690 mL	0.7380 mL	1.8449 mL
	30 mM	0.0615 mL	0.3075 mL	0.6150 mL	1.5374 mL
	40 mM	0.0461 mL	0.2306 mL	0.4612 mL	1.1531 mL
	50 mM	0.0369 mL	0.1845 mL	0.3690 mL	0.9225 mL
	60 mM	0.0307 mL	0.1537 mL	0.3075 mL	0.7687 mL
	80 mM	0.0231 mL	0.1153 mL	0.2306 mL	0.5765 mL

Keywords

Saracatinib

43 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Saracatinib

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Saracatinib

Alle Src Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (43)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Saracatinib Related Classifications

HY-10234 Related Classifications